Lantheus Shareholders Approve Merger with Curium Holdings
Lantheus ( ) has issued an announcement. On October 14, 2026, Lantheus held a special meeting of stockholders, with more than 57 million shares represented out of roughly 65.3 mil ...
Model output · Signal date 2026-10-16
Lantheus Holdings, Inc. (LNTH) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Rating · 90D
▼ Bearish
Exact rating locked
90-day forecast
Sign up free to reveal
30-day forecast
Total
Rank in coverage
Bottom 35%
of 5184 stocks scored
Rank correlation · 90D
12.0%
Spearman, 357 dates
Market Cap
$6.51B
mid-cap · #2 of 17 peers
Summary
Lantheus Holdings, Inc. (LNTH) stock forecast summary
Our AI ranks Lantheus Holdings, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Lantheus Holdings, Inc. is a mid-cap company with a market capitalization of $6.51B. It ranks number 2 by market capitalization among the 17 In Vitro & In Vivo Diagnostic Substances issuers in our coverage with a current forecast.
For LNTH, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 12.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 20.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.1%, buy ≥ +3.4%, sell < +1.8%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, LNTH included.
Follow LNTH freePrice
LNTH price chart and AI forecast
Cross-section · 2026-10-16
How LNTH ranks among 5184 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-06-30
Lantheus Holdings, Inc. (LNTH) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the In Vitro & In Vivo Diagnostic Substances peers listed below that report each metric.
Valuation & Market
| Metric | LNTH | Rank |
|---|---|---|
| Market Cap | $6.51B | 2/17 |
| P/E Ratio | 23.85x | – |
| P/B Ratio | 4.96x | 3/12 |
| EPS | $4.18 | – |
| Book Value/Share | $20.10 | – |
| Revenue/Share | $23.84 | – |
Profitability & Margins
| Metric | LNTH | Rank |
|---|---|---|
| ROE | 21.0% | 2/11 |
| ROA | 11.4% | 2/13 |
| ROIC | 14.5% | 2/12 |
| Gross Margin | 60.1% | 3/9 |
| Operating Margin | 19.4% | 2/14 |
| Net Margin | 17.7% | 2/12 |
| EBT Margin | 23.3% | 2/14 |
| Tax Rate | 24.1% | – |
Financial Health
| Metric | LNTH | Rank |
|---|---|---|
| Current Ratio | 3.06x | 8/16 |
| Quick Ratio | 2.89x | 3/10 |
| D/E Ratio | 0.84x | 5/12 |
| Financial Leverage | 1.84x | 5/12 |
| Interest Coverage | 5.1x | 6/14 |
| Working Capital | $691M | 1/16 |
Cash Flow
| Metric | LNTH | Rank |
|---|---|---|
| Operating Cash Flow | $413M | 2/16 |
| OCF Growth YoY | -21.7% | 4/5 |
Operational Efficiency
| Metric | LNTH | Rank |
|---|---|---|
| Asset Turnover | 0.64x | 4/12 |
| Receivables Turnover | 4.4x | 10/11 |
| Inventory Turnover | 10.8x | 2/10 |
| Fixed Assets Turnover | 10.2x | 1/12 |
| Days Sales Outstanding | 83 days | 2/11 |
| Days Inventory | 34 days | 9/10 |
| Payables Period | 28 days | 8/10 |
| Cash Conversion Cycle | 88 days | 6/8 |
Income Statement
| Metric | LNTH | Rank |
|---|---|---|
| Total Revenue | $1.56B | 3/12 |
| Operating Income | $302M | 2/15 |
| Net Income | $275M | 2/13 |
| R&D Expense | $173M | 5/16 |
| SG&A Expense | $612M | 3/12 |
| Cost of Goods Sold | $620M | 3/10 |
Dividend & Shareholder Information
| Metric | LNTH | Rank |
|---|---|---|
| Shares Outstanding | 65M | – |
| Net Income Growth | 1.6% | – |
| EPS Growth | 11.5% | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $1.03B | 42.5% of assets |
| Cash & Short-term Investments | $593M | 24.6% of assets |
| Accounts Receivable | $353M | 14.6% of assets |
| Inventory | $58M | 2.4% of assets |
| Total Liabilities | $1.10B | 45.7% of assets |
| Short-term Debt | $288M | 11.9% of assets |
Quarterly Financial Reports
LNTH quarterly financials and insider trading
Industry Peers · In Vitro & In Vivo Diagnostic Substances
Lantheus Holdings, Inc. (LNTH) industry peers
Companies classified under the same SEC industry code as Lantheus Holdings, Inc. (In Vitro & In Vivo Diagnostic Substances): 17 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| LNTH Lantheus Holdings, Inc. | ▼ | $6.51B |
| IDXX Idexx Laboratories Inc /De | ▼ | $44.15B |
| NEOG Neogen Corp | ▲ | $2.58B |
| CLDX Celldex Therapeutics, Inc. | ▲ | $2.16B |
| NTLA Intellia Therapeutics, Inc. | ▲ | $1.60B |
| QDEL Quidelortho Corp | ▲ | $885M |
| ACHV Achieve Life Sciences, Inc. | ▲ | $657M |
| MYGN Myriad Genetics Inc | ▲ | $381M |
| TKNO Alpha Teknova, Inc. | ▲ | $380M |
| IMDX Insight Molecular Diagnostics Inc. | ▲ | $98M |
| ICCC Immucell Corp /De/ | ▼ | $98M |
| AWHL Aspira Women's Health Inc. | ▲ | $11M |
| BMRA Biomerica Inc | ▲ | $9M |
| TRIB Trinity Biotech Plc | ▶ | $7M |
| CDIO Cardio Diagnostics Holdings, Inc. | ▲ | $5M |
| QCLS Q/C Technologies, Inc. | ▼ | $4M |
| VNRX Volitionrx Ltd | ▶ | $2M |
Where LNTH sits on the market map
Life Sciences · In Vitro & In Vivo Diagnostic Substances
News
Lantheus Holdings, Inc. (LNTH) stock news
Lantheus Holdings, Inc. (LNTH) Q1 2026 Earnings Call Transcript
Good morning. Welcome to Lantheus' First Quarter 2026 Conference Call. This call is being recorded, and a replay will be available in the Investors section of the company's website approximately 2 ...
Mizuho downgrades Lantheus Holdings to neutral from outperform
Fintel reports that on 13 October 2026, Mizuho downgraded their outlook for Lantheus Holdings (DB:0L8) from Outperform to Neutral. This downgrade follows a prior action by Mizuho on 29 July 2026, when ...
FAQ
Lantheus Holdings, Inc. (LNTH) stock forecast FAQ
What is the Lantheus Holdings, Inc. (LNTH) stock forecast?
Our AI ranks Lantheus Holdings, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Lantheus Holdings, Inc. stock predictions?
For LNTH, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 12.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 20.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Lantheus Holdings, Inc. forecasts updated?
Lantheus Holdings, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Lantheus Holdings, Inc.'s industry peers?
17 issuers in our coverage, LNTH included, share the SEC industry code In Vitro & In Vivo Diagnostic Substances. The largest are: Idexx Laboratories Inc /De (IDXX), Neogen Corp (NEOG), Celldex Therapeutics, Inc. (CLDX), Intellia Therapeutics, Inc. (NTLA), Quidelortho Corp (QDEL), Achieve Life Sciences, Inc. (ACHV).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.